Watchmaker Genomics applies advanced enzymology to enable breakthrough applications for the reading, writing, and editing of DNA and RNA. The company combines domain expertise in protein engineering with large-scale enzyme manufacturing to address the demanding quality, performance, and scale requirements of high-growth clinical genomics applications. Watchmaker's product portfolio includes enzymes and kits for next-generation sequencing library preparation, synthetic biology, and molecular diagnostics.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 06/02/22 | $40,000,000 | Series A |
Decheng Capital Eclipse Ventures | undisclosed |
